Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone

PURPOSE: Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC translocations, with or without BCL2 translocations, have been associated with inferior survival in DLBCL. We investigated...

詳細記述

保存先:
書誌詳細
主要な著者: Johnson, Nathalie A., Slack, Graham W., Savage, Kerry J., Connors, Joseph M., Ben-Neriah, Susana, Rogic, Sanja, Scott, David W., Tan, King L., Steidl, Christian, Sehn, Laurie H., Chan, Wing C., Iqbal, Javeed, Meyer, Paul N., Lenz, Georg, Wright, George, Rimsza, Lisa M., Valentino, Carlo, Brunhoeber, Patrick, Grogan, Thomas M., Braziel, Rita M., Cook, James R., Tubbs, Raymond R., Weisenburger, Dennis D., Campo, Elias, Rosenwald, Andreas, Ott, German, Delabie, Jan, Holcroft, Christina, Jaffe, Elaine S., Staudt, Louis M., Gascoyne, Randy D.
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2012
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC3454768/
https://ncbi.nlm.nih.gov/pubmed/22851565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.41.0985
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料